# US 2025/0205153 A1 · Inhalation composite and carrier based formulation combination

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0205153 A1
- Document ID: US20250205153A1
- Status: Published application
- Kind: A1
- Application number: 18/852,256
- Filed: 2023-03-30
- Published: 2025-06-26
- Earliest claimed: 2022-03-31
- Applicants: Hovione Scientia Limited
- Inventors: Susana SALDANHA; Luis SOUSA; Slavomira DOKTOROVOVA
- Web page: https://patentgrep.com/patent/US20250205153A1

## CPC

- A61K 9/0075: {for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles}
- A61K 9/1617: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/1623: {Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules}
- A61K 9/1694: {resulting in granules or microspheres of the matrix type containing more than 5% of excipient}
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61M 15/0028: {using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up}
- A61M 2202/064: Powder
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}

## Abstract

An inhalable pharmaceutical composition comprises: (i) Spray dried cohesive composite active particles, each composite active particle comprising an active pharmaceutical ingredient (API) material and an excipient; and, (ii) carrier particles Wherein the composite active particles and the carrier particles are blended in a physical mixture. A process of preparing the pharmaceutical composition comprises the steps of: i) providing a solution of an active pharmaceutical ingredient (API) material and a solution of an excipient, which may be separate solutions or a combined solution, and spray drying to provide cohesive composite active particles, wherein each composite active particle comprises an active pharmaceutical ingredient (API) material and an excipient: ii) blending the spray dried cohesive composite active particles with carrier particles to form a physical mixture. The composition may be used in a dry powder inhaler (DPI), particularly a reservoir DPI device.

## Claims

### Claim at position 1

1-31. (canceled)

### Claim 32

An inhalable pharmaceutical composition comprising:
(i) spray dried cohesive composite active particles, each composite active particle comprising an active pharmaceutical ingredient (API) material in an amorphous form and an excipient; and
(ii) carrier particles,
wherein the composite active particles and the carrier particles are blended in a physical mixture and wherein the composite active particles comprise 10% to 85% of the pharmaceutical composition by weight.

### Claim 33 (depends on 32)

A pharmaceutical composition according to claim 32 wherein the composite active particles have a mass median aerodynamic diameter (MMAD) of equal to or less than 10 μm, or
a mass median aerodynamic diameter (MMAD) of equal to or less than 5 μm.

### Claim 34 (depends on 32)

A pharmaceutical composition according to claim 32 comprising one or more of the following features:
(i) wherein the solubility and dissolution rate of the active pharmaceutical ingredient (API) material is higher than that of the crystalline isolated form of the API;
(ii) wherein the composite active particles are more soluble than particles of active pharmaceutical ingredient (API) material alone;
(iii) wherein the composite active particles comprise 10 to 90% of active pharmaceutical ingredient (API) material by weight of the composite active particles.

### Claim 35 (depends on 32)

A pharmaceutical composition according to claim 32 wherein the excipient comprises an amino acid, or a sugar, or a mixture of an amino acid and a sugar.

### Claim 36 (depends on 35)

A pharmaceutical composition according to claim 35 wherein the amino acid comprises leucine, tryptophan, alanine, valine, isoleucine, trileucine, dileucine, methionine, phenylalanine, or proline or a mixture of two or more thereof.

### Claim 37 (depends on 35)

A pharmaceutical composition according to claim 35 wherein the amino acid comprises leucine, isoleucine, trileucine or dileucine or a mixture of two or more thereof.

### Claim 38 (depends on 35)

A pharmaceutical composition according to claim 35 wherein the sugar comprises a disaccharide.

### Claim 39 (depends on 35)

A pharmaceutical composition according to claim 35 wherein the sugar comprises trehalose, lactose, mannitol, or sucrose or a mixture of two or more thereof.

### Claim 40 (depends on 32)

A pharmaceutical composition according to claim 32 wherein the composite active particles comprise about 50 to 85% of the pharmaceutical composition by weight.

### Claim 41 (depends on 32)

A pharmaceutical composition according to claim 32 wherein the carrier particles are selected from lactose, mannitol, trehalose, raffinose, sucrose, microcrystalline cellulose or a mixture of two or more thereof; or wherein,
the carrier particles comprise lactose or lactose monohydrate, or a mixture of lactose and lactose monohydrate.

### Claim 42 (depends on 32)

A pharmaceutical composition according to claim 32 wherein the carrier particles comprise about 15% to 90% of the pharmaceutical composition by weight, or
wherein the carrier particles comprise about 15% to 50% of the pharmaceutical composition by weight.

### Claim 43 (depends on 32)

A pharmaceutical composition according to claim 32 wherein the carrier particles have a mass median aerodynamic diameter (MMAD) of greater than 25 μm; or
wherein the carrier particles have a mass median aerodynamic diameter (MMAD) of from 50 μm to 100 μm.

### Claim 44 (depends on 32)

A process of preparing a pharmaceutical composition according to claim 32 comprising the steps of:
i) providing a solution of an active pharmaceutical ingredient (API) material and a solution of an excipient, which may be separate solutions or a combined solution, and spray drying to provide cohesive composite active particles, wherein each composite active particle comprises an active pharmaceutical ingredient (API) material in an amorphous form and an excipient;
ii) blending the spray dried cohesive composite active particles with carrier particles to form a physical mixture and wherein the composite active particles comprise 10% to 85% of the pharmaceutical composition by weight.

### Claim 45 (depends on 44)

A process of preparing a pharmaceutical composition according to claim 44, wherein after step (i) or after step (ii), or both, a post drying or conditioning step is performed.

### Claim 46 (depends on 44)

A process of preparing a pharmaceutical composition according to claim 44, wherein the composite active particle size distribution is controlled to a Dv50 of equal to or <5 μm.

### Claim 47 (depends on 44)

A process of preparing a pharmaceutical composition according to claim 44 wherein in step (ii) the blending comprises a high shear or a low shear process.

### Claim 48 (depends on 32)

A blister or series of blisters, or one or more capsules, for use in a dry powder inhaler, comprising a pharmaceutical composition according to claim 32.

### Claim 49 (depends on 48)

A dry powder inhaler comprising a blister or series of blisters, or one or more capsules, according to claim 48.

### Claim 50 (depends on 32)

A dry powder inhaler which is a reservoir device, comprising a pharmaceutical composition according to claim 32.

### Claim 51 (depends on 32)

A method of treating a pulmonary condition, said method comprising administering to a patient in need thereof a pharmaceutical composition according to claim 32.
